Constellation Pharmaceuticals Investor Presentation — October 2019

Document content

Stellar Science, Breakthrough Medicine

October 1, 2019Developing Next -Generation

Epigenetic Treatments for

Corporate Overview2

This presentation contains “forward -looking statements” within the meaning of the Private Securities Litigation Reform Act of 19 95 that involve

substantial risks and uncertainties, including statements regarding the implications of preclinical data and the development status of, and

development plans and timelines for, the Company’s product candidates. All statements, other than statements of historical f acts, contained

in this press release, including statements regarding the Company’s strategy, future operations, future financial position, p rospects, plans and

objectives of management, are forward -looking statements. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “e xpect,”

“intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are i ntended to identify forward -

looking statements, although not all forward -looking statements contain these identifying words. Any forward -looking statements are based on

management’s current expectations of future events and are subject to a number of risks and uncertainties that could cause ac tual results to

differ materially and adversely from those set forth in, or implied by, such forward -looking statements. These risks and uncerta inties include,

but are not limited to, risks associated with Constellation’s ability to: obtain and maintain necessary approvals from the FD A and other

regulatory authorities; continue to advance its product candidates in clinical trials; whether preliminary or interim results from preclinical

studies or a clinical trial will be predictive of the final results of a clinical trial; advance the development of its produ ct candidates under the

timelines it anticipates, or at all, in current and future clinical trials; obtain, maintain or protect intellectual property rights related to its product

candidates; manage expenses; and raise the substantial additional capital needed to achieve its business objectives. For a di scussion of

other risks and uncertainties, any of which could cause the Company’s actual results to differ from those contained in the fo rward-looking

statements, see the “Risk Factors” section, as well as discussions of potential risks, uncertainties, and other important fac tors, in the

Company’s most recent filings with the Securities and Exchange Commission. In addition, the forward -looking statements included in this

press release represent the Company’s views as of the date hereof and should not be relied upon as representing the Company’s views as of